Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy

Frontiers in Aging Neuroscience

Volumn 6, Issue JUN, 2014, Pages

  Dauvilliers, Yves A ^a,b   Lehmann, Sylvain ^c   Jaussent, Isabelle ^b   Gabelle, Audrey ^a,c  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c INSERM   (France)

Author keywords

Alzheimer's disease; Cognition; CSF; Hypocretin; Sleep; Tau; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; OREXIN A; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC ACCURACY; EPWORTH SLEEPINESS SCALE; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NARCOLEPSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROTEIN INTERACTION; QUESTIONNAIRE; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SLEEP TIME;

EID: 84904546753     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00119     Document Type: Article

References (37)

1. American Academy of Sleep Medicine. (2005). The International Classification of Sleep Disorders, 2nd Edn. Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine.
2. Bateman, R. J., Wen, G., Morris, J. C., and Holtzman, D. M. (2007). Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68, 666-669. doi: 10.1212/01.wnl.0000256043.50901.e3
3. Baumann, C. R., Dauvilliers, Y., Mignot, E., and Bassetti, C. L. (2004). Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur. Neurol. 52, 73-76. doi: 10.1159/000079749
4. Blennow, K., and Zetterberg, H. (2009). Cerebrospinal fluid biomarkers for Alzheimer's disease. J. Alzheimers Dis. 18, 413-417. doi: 10.3233/JAD-2009-1177
5. Boeve, B. F., Maraganore, D. M., Parisi, J. E., Ahlskog, J. E., Graff-Radford, N., Caselli, R. J., et al. (1999). Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53, 795-800. doi: 10.1212/WNL.53.4.795
6. Braak, H., and Braak, E. (1996). Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165, 3-12. doi: 10.1111/j.1600-0404.1996.tb05866.x
7. Cole, S. L., and Vassar, R. (2008). The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 283, 29621-29625. doi: 10.1074/jbc.R800015200
8. Dauvilliers, Y. (2007). Insomnia in patients with neurodegenerative conditions. Sleep. Med. 8(Suppl. 4), S27-S34. doi: 10.1016/S1389-9457(08)70006-6
9. Dauvilliers, Y., Arnulf, I., and Mignot, E. (2007). Narcolepsy with cataplexy. Lancet 369, 499-511. doi: 10.1016/S0140-6736(07)60237-2
10. Dauvilliers, Y., Baumann, C. R., Carlander, B., Bischof, M., Blatter, T., Lecendreux, M., et al. (2003). CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J. Neurol. Neurosurg. Psychiatry 74, 1667-1673. doi: 10.1136/jnnp.74.12.1667
11. de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327. doi: 10.1073/pnas.95.1.322
12. Duyckaerts, C., Delatour, B., and Potier, M. C. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118, 5-36. doi: 10.1007/s00401-009-0532-1
13. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198. doi: 10.1016/0022-3956(75)90026-6
14. Friedman, L. F., Zeitzer, J. M., Lin, L., Hoff, D., Mignot, E., Peskind, E. R., et al. (2007). In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68, 793-794. doi: 10.1212/01.wnl.0000256731.57544.f9
15. Fronczek, R., van Geest, S., Frolich, M., Overeem, S., Roelandse, F. W., Lammers, G. J., et al. (2012). Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 33, 1642-1650. doi: 10.1016/j.neurobiolaging.2011.03.014
16. Gabelle, A., Roche, S., Geny, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2010). Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res. 1357, 175-183. doi: 10.1016/j.brainres.2010.08.022
17. Gabelle, A., Roche, S., Geny, C., Bennys, K., Labauge, P., Tholance, Y., et al. (2011). Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J. Alzheimers Dis. 26, 553-563. doi: 10.3233/JAD-2011-110515
18. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., de Deyn, P. P., et al. (1999). Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562. doi: 10.1212/WNL.52.8.1555
19. Ju, Y. E., McLeland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S. P., et al. (2013). Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 70, 587-593. doi: 10.1001/jamaneurol.2013.2334
20. Kallweit, U., Hidalgo, H., Engel, A., Baumann, C. R., Bassetti, C. L., and Dahmen, N. (2012). Post H1N1 vaccination narcolepsy-cataplexy with decreased CSF beta-amyloid. Sleep. Med. 13, 323. doi: 10.1016/j.sleep.2011.10.023
21. Kang, J. E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., et al. (2009). Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005-1007. doi: 10.1126/science.1180962
22. Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393. doi: 10.1001/jama.2009.1064
23. McKeith, I. G. (2006). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. 9, 417-423. doi: 10.1212/WNL.47.5.1113
24. McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., et al. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113-1124. doi: 10.1212/WNL.47.5.1113
25. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. doi: 10.1212/WNL.34.7.939
26. McKhann, G. M., Albert, M. S., Grossman, M., Miller, B., Dickson, D., Trojanowski, J. Q., et al. (2001). Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch. Neurol. 58, 1803-1809. doi: 10.1001/archneur.58.11.1803
27. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269. doi: 10.1016/j.jalz.2011.03.005
28. Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., et al. (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553-1562. doi: 10.1001/archneur.59.10.1553
29. Montplaisir, J., Petit, D., Lorrain, D., Gauthier, S., and Nielsen, T. (1995). Sleep in Alzheimer's disease: further considerations on the role of brainstem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep 18, 145-148.
30. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308. doi: 10.1001/archneur.56.3.303
31. Roh, J. H., Huang, Y., Bero, A. W., Kasten, T., Stewart, F. R., Bateman, R. J., et al. (2012). Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer's disease pathology. Sci. Transl. Med. 4, 150ra122. doi: 10.1126/scitranslmed.3004291
32. Slats, D., Claassen, J. A., Lammers, G. J., Melis, R. J., Verbeek, M. M., and Overeem, S. (2012). Association between hypocretin-1 and amyloid-beta42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr. Alzheimer Res. 9, 1119-1125. doi: 10.2174/156720512804142840
33. Slats, D., Claassen, J. A., Verbeek, M. M., and Overeem, S. (2013). Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res. Rev. 12, 188-200. doi: 10.1016/j.arr.2012.04.003
34. Spira, A. P., Gamaldo, A. A., An, Y., Wu, M. N., Simonsick, E. M., Bilgel, M., et al. (2013). Self-reported sleep and beta-amyloid deposition in community-dwelling older adults. JAMA Neurol. 70, 1537-1543. doi: 10.1001/jamaneurol.2013.4258
35. Tononi, G., and Cirelli, C. (2006). Sleep function and synaptic homeostasis. Sleep. Med. Rev. 10, 49-62. doi: 10.1016/j.smrv.2005.05.002
36. Wennstrom, M., Londos, E., Minthon, L., and Nielsen, H. M. (2012). Altered CSF orexin and alpha-synuclein levels in dementia patients. J. Alzheimers Dis. 29, 125-132. doi: 10.3233/JAD-2012-111655
37. Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., et al. (2013). Sleep drives metabolite clearance from the adult brain. Science 342, 373-377. doi: 10.1126/science.1241224